“It’s now a very popular program that touches a very broad cross-section of American society,” said Drew Altman, president of the health care research firm KFF.
GOP once maligned Medicaid. Now some see a program too big to touch
→
“It is about political signaling in a campaign much more than it is about demonstrating for people that they benefit from the insulin cap,” said Drew Altman, president and CEO of KFF, a nonprofit that researches health care issues.
Joe Biden sees $35 price cap for insulin as pivotal campaign issue, but it isn't so clear-cut
→